Our top pick for
U.S. Concrete Inc is a building materials business based in the US. U-SConcrete shares (USCR) are listed on the NASDAQ and all prices are listed in US Dollars. U-SConcrete employs 2,967 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$56.15|
|52-week range||$71.75 - $74.73|
|50-day moving average||$73.14|
|200-day moving average||$66.23|
|Wall St. target price||$69.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.19|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-24)||N/A|
|1 month (2022-06-01)||N/A|
|3 months (2022-04-01)||N/A|
|6 months (2022-01-01)||N/A|
|1 year (2021-07-02)||-24.19%|
|2 years (2020-07-02)||130.88%|
|3 years (2019-07-05)||9.71%|
|5 years (2017-07-03)||78.7|
Valuing U-SConcrete stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of U-SConcrete's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
U-SConcrete's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8948. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into U-SConcrete's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
U-SConcrete's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $146.7 million.
The EBITDA is a measure of a U-SConcrete's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.3 billion|
|Operating margin TTM||3.44%|
|Gross profit TTM||$315.6 million|
|Return on assets TTM||1.88%|
|Return on equity TTM||-1.19%|
|Market capitalisation||$1.3 billion|
TTM: trailing 12 months
We're not expecting U-SConcrete to pay a dividend over the next 12 months.
Over the last 12 months, U-SConcrete's shares have ranged in value from as little as $71.75 up to $74.73. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while U-SConcrete's is 1.3421. This would suggest that U-SConcrete's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
U. S. Concrete, Inc. , through its subsidiaries, produces and sells ready-mixed concrete, aggregates, and concrete-related products and services to the construction industry in the United States, the U. S. Virgin Islands, and Canada. It operates through two segments, Ready-Mixed Concrete and Aggregate Products.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.